Contrast shortage update: FDA opens door for U.S. providers to order foreign-labeled Bayer contrast media

The U.S. Food and Drug Administration has granted Bayer permission to import foreign-labeled Ultravist (iopromide) to help temper the ongoing impact of the iodinated contrast media shortage

Per Bayer’s communications, the contrast agent is manufactured at the same site in Berlin, Germany as the Ultravist that is intended for U.S. markets, but due to its intended distribution abroad it lacks current FDA-approved labeling. 

“In response to iodinated contrast media shortages, due to supply pressures resulting from COVID-19 lockdowns in China, Bayer has engaged with the United States Food and Drug Administration to import and distribute a limited quantity of Ultravist® (iopromide) stock which was originally intended and labeled for foreign markets.” 

This is just one of many mitigation measures that suppliers and imaging organizations have deployed in an attempt to lessen the ramifications caused by the contrast media shortage. When news broke that GE’s Shanghai manufacturing facility had been temporarily shut down in the spring, GE—the United States’ largest supplier of iodinated contrast—indicated that the matter would resolve by late June. But now more than halfway through July, many organizations have a less optimistic outlook, with some indicating the potential for the supply shortage to linger until late September

In GE’s most recent update on July 15, they shared that their Shanghai facilities continue to work at full capacity. However, they expect “some ongoing reduced availability of iodinated contrast media as we continue to restabilize global supply.” 

Health Imaging will continue to share updates on the shortage as they become available. 

 

Hannah murhphy headshot

In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She joined Innovate Healthcare in 2021 and has since put her unique expertise to use in her editorial role with Health Imaging.

Around the web

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.